Is Immatics N.V. a good investment? Immatics N.V. (IMTX) is currently trading at 6.39 USD. Market analysts have a consensus price target of 16.40 USD. This suggests a potential upside from current levels.
Earnings Schedule: Immatics N.V. is expected to release its next earnings report on Nov. 17, 2026. The market consensus estimate for Forward EPS is -2.03.
No, it does not currently pay a dividend.
Immatics N.V. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Nov. 17, 2026. The company currently has a trailing EPS of -1.92.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Community Discussion